Brought to you by 
Laboratorios Almirall gets rights to Ironwood's linaclotide in Europe; later gets rights in Mexico
03 Jun 2021
Executive Summary
Spanish pharmaco Laboratorios Almirall SA (respiratory, autoimmune, and dermatology therapeutics) received exclusive European rights to develop and commercialize Ironwood Pharmaceuticals' (mainly gastrointestinal and cardiovascular therapeutics) GI compound linaclotide.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Laboratorios Almirall gets rights to Ironwood's linaclotide in Europe; later gets rights in Mexico
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice